Pacific Cancer Care

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Gastric and oesophageal cancer3 trials
• Multiple myeloma3 trials
• Prostate cancer3 trials
• Metastatic breast cancer2 trials
• Myelodysplastic syndromes2 trials
• Acute myeloid leukaemia1 trial
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Colorectal cancer1 trial
• Glioblastoma1 trial
• Kidney cancer1 trial
• and 5 more

Phase

• Phase 36 trials
• Phase 13 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Active, not recruiting6 trials
• Completed5 trials
• Recruiting3 trials
• Terminated3 trials

Lead sponsor

• Daiichi Sankyo2 trials
• N-Power Medicine2 trials
• Aptose Biosciences Inc.1 trial
• Astellas Pharma Global Development, Inc.1 trial
• Bristol-Myers Squibb1 trial
• and 10 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

  Contact: Michael Koontz, Site 0407

• Recruiting

  An External Control Arm Study in Non-Small Cell Lung Cancer

  NCT07174388· N-Power Medicine· Source

  Contact: Alexander Baskoro

• Recruiting

  Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

  NCT07028489· N-Power Medicine· Source

  Contact: Study Coordinator

• Active, not recruiting

  Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

  NCT05501886· Phase 3· Celcuity Inc· Source

• Recruiting

  Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

  NCT05297734· Stanford University· Source

  Contact: Manali I Patel, MD MPH MS

• Active, not recruiting

  A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

  NCT03653507· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

  NCT03706365· Phase 2/3· Eli Lilly and Company· Source

• Active, not recruiting

  Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

  NCT03236428· Phase 2· Dana-Farber Cancer Institute· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting

Closed trials

• Completed

  Whole Food Plant-based Diet to Improve Outcomes in Prostate Cancer

  NCT07220499· Pacific Cancer Care· Source

• Completed

  Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

  NCT05605964· Phase 3· Sumitomo Pharma America, Inc.· Source

• Completed

  DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

  NCT04014075· Phase 2· Daiichi Sankyo· Source

• Completed

  A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

  NCT03984097· Phase 1· Takeda· Source

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

  NCT03893682· Phase 1· Aptose Biosciences Inc.· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

  NCT03110822· Phase 1· Oncotherapeutics· Source

  Contact: James R Berenson, MD

• Terminated

  Connect® Myeloid Disease Registry

  NCT01688011· Celgene· Source